EPIX - Biotech Pre-earnings Run LONGEPIX on the 15-minute chart shows a solid trend up with a set of moving averages as the
guardrails now in a bit of a pullback. The after-hours price action will not appear on the chart
but price jumped 5%. Earnings are anticipated for 2/8 or 2/9 as best as I can tell. Internet
search information is not consistent. So, if tomorrow this is still pre-earnings but price popped
5% overnight, I will take a small long position. If the price is still pulled back to the slowest
moving average, I will take a larger position. No matter I will assess it on a 3-5 minute time
frame and recheck internet information regarding an earnings report. One news catalyst is that
Secretary of Defense has been in and out of the hospital ( DC VAMC) with prostate cancer
and maybe currently getting treatment in a clinical trial of an EPIX drug per the NIH
in Bethesda. Biotech is forecasted to be one of the hottest sectors for 2024. EPIX has
a trend up that impresses me. I will go long on this when I find a best entry and possibly in the
next trading session. The options chain is minimal volume as so represents a liquidity trap.
I will not go there.
EPIX
EPIX Big Push Forward - 86% Up IN ONE MONTHESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
SHORT INTEREST
102.77K 08/15/19
P/E Current
-1.08
P/E Ratio (with extraordinary items)
-1.45
Average Recommendation: BUY
Average Target Price: 18.63